HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moran, A. Articles by Nair, K. S. Search for Related Content PubMed PubMed Citation Articles by Moran, A. Articles by Nair, K. S. Social Bookmarking                What's this?

Protein Metabolism in Clinically Stable Adult Cystic Fibrosis Patients With Abnormal Glucose Tolerance

¹ Endocrinology and
² Pulmonology, Department of Pediatrics, and the
³ Department of Radiology, University of Minnesota, Minneapolis
⁴ Division of Endocrinology, Mayo Clinic and Foundation, Rochester, Minnesota

Cystic fibrosis (CF) patients are reported to experience chronic protein catabolism. Since diabetes or impaired glucose tolerance (IGT) is common in CF, we hypothesized that their protein catabolic state is related to reduced insulin secretion or reduced insulin action. A total of 12 clinically stable adult CF patients with abnormal glucose tolerance and 12 age-, sex-, and lean body mass–matched healthy control subjects underwent protein turnover studies using L-[1-¹³C]leucine, L-[¹⁵N]phenylalanine, and L-[²H₄]tyrosine, with and without exogenous insulin infusion. In the baseline fasting state, protein metabolism was entirely normal in CF patients, with no evidence of increased protein catabolism. In contrast, striking abnormalities were seen in CF patients when insulin was infused, since they did not experience normal suppression of the appearance rates of leucine, phenylalanine, or tyrosine (indexes of protein breakdown). At an insulin concentration of 45 ± 2 µU/ml, normal control subjects suppressed the leucine appearance rate by 19 ± 5% (P < 0.01), ketoisocaproate appearance rate by 10 ± 3% (P = 0.03), tyrosine appearance rate by 11 ± 2% (P = 0.03), and phenylalanine appearance rate by 6 ± 3% (P = 0.07). Phenylalanine conversion to tyrosine decreased by 22 ± 7% (P = 0.03). At a similar insulin concentration of 44 ± 3 µU/ml, normal suppression of amino acid appearance did not occur in CF. The leucine appearance rate decreased by 4 ± 2% (P = 0.65), ketoisocaproate appearance rate by 1 ± 2% (P = 0.94), tyrosine appearance rate by 0 ± 6% (P = 0.56), phenylalanine appearance rate by 5 ± 6% (P = 0.34), and phenylalanine conversion to tyrosine by 5 ± 6% (P = 0.95). Poor suppression of the amino acid appearance rate in CF was not related to previously documented glucose tolerance status (IGT or CF-related diabetes without fasting hyperglycemia), fasting insulin levels, the acute insulin response, insulin sensitivity, cytokine or counterregulatory hormone levels, resting energy expenditure, caloric intake, pulmonary function, or clinical status. Protein synthesis was not significantly affected by insulin infusion in either normal control subjects or CF patients. In conclusion, clinically stable adult CF patients have normal indexes of protein breakdown and synthesis in the fasting state. In contrast, elevation of plasma insulin to physiological postprandial levels fails to normally suppress indexes of protein breakdown. It is therefore likely that inability to spare protein during the postprandial state is the cause of protein catabolism in these patients.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. E. Milla, J. Billings, and A. Moran Diabetes Is Associated With Dramatically Decreased Survival in Female but Not Male Subjects With Cystic Fibrosis Diabetes Care, September 1, 2005; 28(9): 2141 - 2144. [Abstract] [Full Text] [PDF]

				M. Rafii, K. Chapman, C. Stewart, E. Kelly, A. Hanna, D. C Wilson, E. Tullis, and P. B Pencharz Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis Am. J. Clinical Nutrition, February 1, 2005; 81(2): 421 - 426. [Abstract] [Full Text] [PDF]

				S. Tofe, J. C Moreno, L. Maiz, M. Alonso, H. Escobar, and R. Barrio Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis Eur. J. Endocrinol., February 1, 2005; 152(2): 241 - 247. [Abstract] [Full Text] [PDF]

				D. Darmaun, V. Hayes, D. Schaeffer, S. Welch, and N. Mauras Effects of Glutamine and Recombinant Human Growth Hormone on Protein Metabolism in Prepubertal Children with Cystic Fibrosis J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1146 - 1152. [Abstract] [Full Text] [PDF]

				V. Figueroa, C. Milla, E. J Parks, S. J. Schwarzenberg, and A. Moran Abnormal lipid concentrations in cystic fibrosis Am. J. Clinical Nutrition, June 1, 2002; 75(6): 1005 - 1011. [Abstract] [Full Text] [PDF]

				C. Brunzell and S. J. Schwarzenberg Cystic Fibrosis-Related Diabetes and Abnormal Glucose Tolerance: Overview and Medical Nutrition Therapy Diabetes Spectr, April 1, 2002; 15(2): 124 - 127. [Full Text] [PDF]

				A. Moran, J. Phillips, and C. Milla Insulin and Glucose Excursion Following Premeal Insulin Lispro or Repaglinide in Cystic Fibrosis-Related Diabetes Diabetes Care, October 1, 2001; 24(10): 1706 - 1710. [Abstract] [Full Text] [PDF]